ArticleOncoimmunology2013
Immune effectors required for the therapeutic activity of vorinostat.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.BMC cancer · 2021Article
- Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.Cancer biology & therapy · 2019Article
- A broad-spectrum antibiotic, DCAP, reduces uropathogenic Escherichia coli infection and enhances vorinostat anticancer activity by modulating autophagy.Cell death & disease · 2018Article
- Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.Scientific reports · 2016Article
- Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells.Translational research : the journal of laboratory and clinical medicine · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Immunogenic cell death inducers as anticancer agents.Oncotarget · 2014Article
- Trial Watch: Proteasomal inhibitors for anticancer therapy.Molecular & cellular oncologyReview
- An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.